Table 1.
Summary of anti-VEGF drugs.
| Name | Commercial Name | Sponsor | Approved Year | Type | MOA | Doses | Interval |
|---|---|---|---|---|---|---|---|
| Bevacizumab | Avastin | Genentech | Off label | mAb | VEGFA inhibition | 1.25 mg/0.05 mL | Q1M |
| Pegaptanib | Macugen | Bausch/Lomb | 2004 | aptamer | VEGFA165 inhibition | 0.3 mg/0.09 mL | Q6W |
| Ranibizumab | Lucentis | Genentech | 2006 | Fab | VEGFA inhibition | 0.5 mg/0.05 mL | Q1M |
| Aflibercept | Eylea | Regeneron | 2011 | FcFP | VEGFA, VEGFB, and PGF inhibition | 2 mg/0.05 mL | Q1M for 3M and then Q2M |
| Conbercept | Lumitin | Cheongdu Kanghong Biotech | 2013 (China) | FcFP | VEGFA, VEGFB, and PGF inhibition | 0.5 mg/0.05 mL | Q1M for 3M and then Q3M |
| Brolucizumab | Beovu | Norvatis | 2019 | scFv | VEGFA inhibition | 6 mg/0.05 mL | Q1M for 3M and then Q2-3M |
| Ranibizumab ocular implant | Susvimo | Genentech | 2021 | mAb implnat | VEGFA inhibition | 2 mg/0.02 mL, continuously released for 6 months | Refill Q24W |
| Faricimab | Vabysmo | Genentech | 2022 | mAb | VEGFA and Ang2 inhibition | 6 mg/0.05 mL | Q1M for 4M and then Q2-3M |
Approval year is based on US FDA approval, if not indicated. Q, Latin quaque, means each; Q1M means once monthly.